[1] Takagi S, Tsuji T, Amagai T, et al. Specific cell surface labels in the visual centers of Xenopus laevis tadpole identified using monoclonal antibodies. Dev Biol, 1987. 122(1): p. 90-100.[2] Bielenberg DR, Pettaway CA, Takashima S, et al. Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res, 2006. 312(5): p. 584-93.[3] 张红闯,陈洁,宋晓萌,等. Nrp1、Nrp2及SEMA3F在口腔癌组织及TCa、ACC细胞系中的表达及其可能的作用[J]. 口腔医学,2009,29(5):235—238[4] 张阳,傅振,宋晓萌,等. Semaphorin3A及其受体在舌鳞癌中的表达及作用[J]. 口腔生物医学,2011, 02(1):21—25[5] Starzec A, Ladam P, Vassy R, et al. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides, 2007. 28(12): p. 2397-402.[6] Binétruy-Tournaire R, Demangel C, Malavaud B, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis[J]. The EMBO Journal, 2000, 19:1525–1533.[7] Wey JS, Gray MJ, Fan F, et al. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer, 2005. 93(2): p. 233-41.[8] Raskopf E, Vogt A, Standop J, et al. Inhibition of neuropilin-1 by RNA-interference and its angiostatic potential in the treatment of hepatocellular carcinoma. Z Gastroenterol, 2010. 48(1): p. 21-7.[9] Li X, Tang T, Lu X, et al. RNA interference targeting NRP-1 inhibits human glioma cell proliferation and enhances cell apoptosis. Mol Med Rep, 2011. 4(6): p. 1261-6.[10] Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J, 1999. 13(1): p. 9-22. |